This case report describes the use of low-dose naltrexone (LDN) in a patient with systemic sclerosis experiencing severe pruritus unresponsive to conventional treatments. Administration of LDN at 4.5 mg nightly resulted in significant improvement in pruritus intensity and sleep quality within two weeks, with sustained benefits over several months. The
This 2018 case report describes a multimodal approach to treating a patient with concurrent postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS). The regimen included low-dose naltrexone (LDN), intravenous immunoglobulin (IVIg), and rifaximin for small intestinal bacterial overgrowth (SIBO). The patient reported significant symptom improvement across multiple
This 2006 case report describes the long-term survival of a patient with metastatic pancreatic cancer following treatment with an integrative protocol centered around intravenous alpha-lipoic acid (ALA) and oral low-dose naltrexone (LDN). Diagnosed with pancreatic cancer and liver metastases and given a poor prognosis, the patient underwent the ALA/LDN regimen
This 2018 case report presents the clinical course of a patient with Stage IV renal cell carcinoma who achieved long-term survival following an integrative treatment protocol initiated after failure of conventional therapies. The regimen included intravenous α-lipoic acid, vitamin C, low-dose naltrexone (LDN), hydroxycitrate, and comprehensive lifestyle changes. The treatment
This case report details the treatment of six prostate cancer patients, some with metastatic disease, using a combination of the immunomodulator IMM-101 (a heat-killed whole-cell mycobacterium), vitamin D3 correction, and anti-inflammatory agents such as bromelain and low-dose naltrexone (LDN). The combination therapy led to reductions in prostate-specific antigen (PSA) levels
This 2024 review explores the potential of low-dose naltrexone (LDN) as an adjunct in cancer treatment. LDN functions by transiently blocking the opioid growth factor receptor (OGFr), leading to a compensatory increase in opioid growth factor (OGF) levels, which inhibits cancer cell proliferation. Additionally, LDN modulates the immune system by
This 2018 review explores the pharmacological properties and therapeutic applications of low-dose naltrexone (LDN), defined as daily doses between 1 and 5 mg. LDN modulates the immune system by transiently blocking opioid receptors, leading to upregulation of endogenous opioids and reduction of pro-inflammatory cytokines via Toll-like receptor 4 (TLR4) antagonism.
This 2021 study investigates the antitumor effects of low-dose naltrexone (LDN) on cervical cancer. LDN treatment upregulated the expression of the opioid growth factor receptor (OGFr) and suppressed the PI3K/AKT/mTOR signaling pathway, leading to reduced proliferation, migration, and invasion of cervical cancer cells in vitro. In vivo, LDN inhibited tumor
This 2014 prospective case series evaluated the safety and potential efficacy of a metabolic therapy regimen in 10 patients with advanced, chemoresistant metastatic cancers. The treatment combined intravenous alpha-lipoic acid (600 mg), oral hydroxycitrate (500 mg three times daily), and low-dose naltrexone (5 mg at bedtime). Patients included those with
This 2021 systematic review evaluates the effects of naltrexone (NTX), including low-dose naltrexone (LDN), on cancer progression and mortality across human, animal, and cell culture studies. Findings indicate that LDN (3–5 mg/day) may inhibit tumor growth and metastasis, potentially by modulating opioid receptors and immune responses. Conversely, high-dose or continuous
